文献速递儿童内分泌与遗传代谢儿童消化与营养

GLP-1受体激动剂在儿童青少年肥胖或2型糖尿病中的疗效与安全性:系统综述与Meta分析

Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Pediatr · 2025-01-01

该系统综述与Meta分析纳入18项RCT共1402名儿童青少年,评估GLP-1受体激动剂对比安慰剂的疗效与安全性。结果显示GLP-1受体激动剂显著降低HbA1c、空腹血糖、体重、BMI、BMI SDS、BMI百分位和收缩压,但增加胃肠道不良事件。自杀意念或行为等其他不良事件无显著差异。

要点

  • GLP-1受体激动剂显著改善儿童青少年肥胖或2型糖尿病患者的血糖、体重及心血管代谢指标。
  • 胃肠道不良事件风险增加,需在长期管理中关注。
  • 现有数据随访时间较短,自杀意念或行为等不良事件无显著差异。

核心结论

  • 在18项RCT的Meta分析中,GLP-1受体激动剂显著改善儿童青少年2型糖尿病或肥胖患者的血糖、体重和心血管代谢结局。

研究设计与样本

  • 系统检索PubMed、Embase和Cochrane CENTRAL从建库至2025年2月28日的RCT,纳入18项RCT(11项肥胖、6项2型糖尿病、1项糖尿病前期),共1402名受试者(GLP-1受体激动剂组838例,安慰剂组564例),平均年龄13.7岁(范围6-17岁),女性831例(59.3%),中位治疗时长0.51年(IQR 0.25-1.00)。

主要发现

  • GLP-1受体激动剂显著降低HbA1c(-0.44%;95% CI,-0.68%至-0.21%)、空腹血糖(-9.92 mg/dL;95% CI,-16.20至-3.64)、体重(-3.02 kg;95% CI,-4.98至-1.06)、BMI(-1.45;95% CI,-2.40至-0.49)、BMI SDS(-0.20;95% CI,-0.36至-0.05)、BMI百分位(-7.24%;95% CI,-12.97%至-1.51%)和收缩压(-2.73 mm Hg;95% CI,-4.04至-1.43)。
  • GLP-1受体激动剂增加胃肠道不良事件(log[率比] [RR],0.75)。
  • 其他不良事件包括自杀意念或行为无显著差异。

关键数值与推荐

  • 主要疗效结局包括HbA1c变化(百分点)、空腹血糖(mg/dL)、体重(kg)、BMI、BMI z评分或百分位、BMI标准差评分(SDS)、血脂结局和血压。
  • 安全性结局包括胃肠道不良事件、感染、肝胆疾病、自杀意念或行为、抑郁、低血糖和因不良事件停药。

临床怎么用

  • 对于儿童青少年肥胖或2型糖尿病患者,GLP-1受体激动剂可显著改善血糖、体重和心血管代谢指标。
  • 需关注胃肠道不良事件,并在长期管理中加以监测。

局限性

  • 随访时间相对较短,中位治疗时长0.51年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Obesity affects 1 in 5 children and adolescents, increasing the risk of type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the few pharmacotherapy options available for this population, necessitating a comprehensive evaluation of efficacy and safety. OBJECTIVE: To assess the efficacy and safety of GLP-1 RAs in children and adolescents (<18 years) with obesity, prediabetes, or T2D. DATA SOURCES: A systematic search was conducted in PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) for randomized clinical trials (RCTs) published from inception until February 28, 2025. Data analysis was completed from January 2025 to April 2025. STUDY SELECTION: RCTs comparing GLP-1 RAs to placebo in children and adolescents with obesity, overweight, prediabetes, or T2D with reported safety and efficacy data were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data on sample size, population, interventions, follow-up, and outcomes. Risk of bias was assessed using version 2 of the Cochrane risk of bias tool (RoB2). Efficacy outcomes (except lipids) were analyzed as estimated treatment differences, lipids as estimated treatment ratios, and safety via rate ratios. A random-effects inverse variance model was used for all outcomes. MAIN OUTCOMES AND MEASURES: The primary efficacy outcomes were change in hemoglobin A1c (HbA1c) (in percentage points), fasting glucose (in milligrams per deciliter), body weight (in kilograms), body mass index (BMI, calculated as weight in kilograms divided by height in meters squared), BMI z scores or percentiles, BMI standard deviation score (SDS), lipid outcomes, and blood pressure. Exploratory efficacy outcomes included obstructive sleep apnea and metabolic dysfunction-associated steatohepatitis or metabolic dysfunction-associated steatotic liver disease. Safety outcomes included gastrointestinal adverse effects (GI AEs), infections, hepatobiliary disorders, suicidal ideation or behaviors, depression, hypoglycemia, and adverse event discontinuations. RESULTS: A total of 18 RCTs (11 in obesity, 6 in T2D, and 1 in prediabetes) with 1402 participants (838 GLP-1 RA users and 564 placebo) were included (mean [range] age, 13.7 [6-17] years; 831 female participants (59.3%); median [IQR] treatment duration, 0.51 [0.25-1.00] years). GLP-1 RAs significantly reduced HbA1c (-0.44%; 95% CI, -0.68% to -0.21%), fasting glucose (-9.92 mg/dL; 95% CI, -16.20 to -3.64), body weight (-3.02 kg; 95% CI, -4.98 to -1.06), BMI (-1.45; 95% CI, -2.40 to -0.49), BMI SDS (-0.20; 95% CI, -0.36 to -0.05), BMI percentile (-7.24%; 95% CI, -12.97% to -1.51%), and systolic blood pressure (-2.73 mm Hg; 95% CI, -4.04 to -1.43) and increased GI AE (log[rate ratio] [RR], 0.75). Other AEs, including suicidal ideation or behaviors, showed no significant differences. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis of 18 trials, GLP-1 RAs significantly improved glycemic, weight, and cardiometabolic outcomes in children and adolescents with T2D or obesity. Available data over a relatively short follow-up suggested suicidal ideation or behaviors were not significantly different, although GI AEs warrant attention in long-term management.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Kotecha P, Huang W, Yeh YY, et al. Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis. JAMA Pediatr. 2025. PMID: 40952752. doi:10.1001/jamapediatrics.2025.3243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。